The History and Development of HER2 Inhibitors

Xiaohui Xia; Chen Gong; Yinan Zhang; Huihua Xiong

doi:10.3390/ph16101450

Pharmaceuticals (Oct 2023)

The History and Development of HER2 Inhibitors

Xiaohui Xia,
Chen Gong,
Yinan Zhang,
Huihua Xiong

Affiliations

Xiaohui Xia: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Chen Gong: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Yinan Zhang: School of Chemical Science and Engineering, Tongji University, Shanghai 200092, China
Huihua Xiong: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

DOI: https://doi.org/10.3390/ph16101450
Journal volume & issue: Vol. 16, no. 10
p. 1450

Abstract

Read online

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.

Published in Pharmaceuticals

ISSN: 1424-8247 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Pharmacy and materia medica
Website: http://www.mdpi.com/journal/pharmaceuticals/

About the journal

Abstract

Keywords